UBS AG has taken a significant step in the structured investment market by filing a preliminary pricing supplement for contingent income auto-callable securities linked to The Goldman Sachs Group, Inc. This move highlights UBS's commitment to providing innovative financial products in the national commercial banking sector.
The filing, dated November 12, 2026, outlines the terms and conditions for these securities, which offer investors the opportunity to earn contingent payments based on the performance of Goldman Sachs' common stock. The securities are designed to provide returns linked to the underlying equity while also incorporating risk factors that investors must consider.
Company Background
UBS AG, incorporated in Switzerland, operates primarily in the national commercial banking sector (SIC 6021). The company is publicly traded on the New York Stock Exchange under multiple tickers, including AMUB and BDCX. UBS has a long-standing reputation for its wealth management and investment banking services, catering to a global clientele.
What the Filing Says
The filing states, "The information in this preliminary pricing supplement is not complete and may be changed." It emphasizes that the securities will be issued under registration statement No. 333-283672 and are subject to certain conditions and risks.
Impact
This new offering may attract a variety of investors, particularly those interested in structured products that provide exposure to U.S. equities. By linking the securities to Goldman Sachs, UBS is likely targeting investors looking for potential income opportunities while being aware of the inherent risks involved.
What's Next
Further details regarding the pricing and final terms of these securities are expected as UBS continues to finalize the offering. The filing does not specify what happens next, but the pricing date is anticipated to be November 20, 2026.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










